# OnCo record imbrave150 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/imbrave150/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "imbrave150", "NCT03434379" ;
  schema:name "IMbrave150"@en ;
  schema:description "The trial that ended the sorafenib era: immunotherapy plus an anti-VEGF antibody became the new first-line standard for liver cancer."@en ;
  schema:url <https://onco.cc/trials/imbrave150/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03434379>, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366100/> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-03-15" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:people <https://onco.cc/people/richard-finn/>, <https://onco.cc/people/ann-lii-cheng/>, <https://onco.cc/people/lim-ho-yeong/> .